Patent US1242970A successfully refreshed from Google Patents.
Patent EP0187041B1 successfully refreshed from Google Patents.
EP0187041B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Fusions of AIDS-related polypeptides
Assignee: Genentech Inc
•
Filing: 1985-12-23
•
Granted: 1996-05-15
•
Expires: 2005-12-23
Abstract
Abstract Diagnostic product and vaccine for Acquired Immuno-deficiency Syndrome AIDS) and methods for making and using same, wherein viral polypeptide sequences from an AIDS associated retrovirus are expressed directly or as a fusion polypeptide in a prokaryotic or mammalian cell expression host to produce a diagnostic product which specifically binds complementary antibody produced by individuals afflicted with AIDS or a vaccine against AIDS which confers resistance to infection by AIDS associated retrovirus. The reverse transcriptase of an AIDS associated retrovirus is used separately or in a whole cell assay to identify compounds which selectively inhibit retroviral reverse transcriptase.
Inventors
- 👤 Daniel Jeffrey Capon
- 👤 Laurence Allan Lasky
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 23:55
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; C07K14/195; C07K14/24; C07K14/245; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/62; C12Q; C12Q1/00; C12Q1/48; A; A61; A61K; A61K39/00; C07K2319/00; C07K2319/01; C07K2319/02; C07K2319/40; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16111; C12N2740/16122
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
92 words
A fusion polypeptide comprising (a) a first polypeptide sequence of an AIDS associated retrovirus E', env or gag polypeptide having at least one antigenic determinant capable of specifically binding complementary antibody and (b) a second polypeptide sequence which is not an AIDS associated virus polypeptide; wherein said E' polypeptide of AIDS-associated retrovirus is defined as the 206 residue polypeptide designated "E'" in Fig. 2, its naturally-occurring alleles, or its amino acid sequence variants which are immunologically cross-reactive with antisera capable of binding the E' polypeptide produced in cells infected with AIDS-associated retrovirus.
Claim 2
Dependent Claim
26 words
The fusion polypeptide of claim 1 wherein the amino terminus of the first polypeptide sequence is fused to the carboxyl terminus of the second polypeptide sequence.
Claim 3
Dependent Claim
13 words
The fusion polypeptide'of claim 1 wherein the second polypeptide is a eukaryotic polypeptide.
Claim 4
Dependent Claim
19 words
The fusion polypeptide of claim 3 wherein the eukaryotic polypeptide is an interferon, insulin or human growth hormone sequence.
Claim 5
Dependent Claim
14 words
The fusion of claim 3 wherein the second polypeptide is not a yeast polypeptide.
Claim 6
Dependent Claim
28 words
The fusion of claim 3, 4 or 5 wherein the eukaryotic polypeptide is positioned at the amino terminus, carboxy terminus, or inserted within the AIDS associated polypeptide sequence.
Claim 7
Dependent Claim
13 words
The fusion of claim 1 wherein the second polypeptide is a viral antigen.
Claim 8
Dependent Claim
14 words
The fusion of claim 7 wherein the viral antigen is a herpes simplex antigen.
Claim 9
Dependent Claim
13 words
The fusion of claim 7 wherein the second polypeptide is a prokaryotic polypeptide.
Claim 10
Dependent Claim
15 words
The fusion of any of claims 1-9 wherein the retrovirus polypeptide is gp120 or gp160.
Claim 11
Dependent Claim
20 words
The fusion of any of claims 1-10 wherein the second polypeptide is capable of inducing an autoimmune response in humans.
Claim 12
Dependent Claim
21 words
The fusion of any of claims 1-10 wherein the second polypeptide is not capable of inducing an autoimmune response in humans.
Claim 13
Dependent Claim
15 words
The fusion of any of claims 1-12 wherein the retrovirus polypeptide is an E' sequence.
Claim 14
Dependent Claim
10 words
The fusion of any of claims 1-13 which is unglycosylated.
Claim 15
Dependent Claim
17 words
A composition consisting essentially of the fusion of any of claims 1-14 and a pharmaceutically acceptable vehicle.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.